Ember Therapeutics, Inc. has closed an exclusive license deal with Joslin Diabetes Center. This license deal is for intellectual property covering a bone morphogenetic protein (BMP7) which plays a role in regulating brown fat development. Brown fat, along with white fat, are the two types of fat in humans and other mammals. Ember is carrying out a number of large and small molecule programs which increase and activate the body s brown fat, strengthening the natural ability to efficiently burn fuel stores including glucose and lipids to decrease stored calories in the body. Besides this licensing deal, Joslin will carry out research services for Ember through Joslin Technologies.